Systemic Juvenile Idiopathic Arthritis
(SJIA)
ACTEMRA is the first and only FDA-approved treatment for systemic juvenile idiopathic arthritis (SJIA). In this section you’ll learn more about ACTEMRA as a first-line biologic for children 2 years and up.
Systemic Juvenile Idiopathic Arthritis (SJIA)
ACTEMRA is the first and only FDA approved treatment for systemic juvenile idiopathic arthritis (SJIA). In this section you’ll learn more about ACTEMRA as a first-line biologic for children 2 years and up.

  • Proven EfficacySJIA patients showed significant results including significant systemic and articular improvements while taking ACTEMRA.

    See the clinical data

  • Safety Profile and Laboratory TestsSee the ACTEMRA safety profile in SJIA and laboratory tests for patients with SJIA.

    Learn more

  • Dosing and AdministrationView ACTEMRA dosing information and find a helpful tool to easily determine your patient’s ACTEMRA dosage.

    Go now

  • Patient and Caregiver ResourcesFind the information and resources your patients and their caregivers need for managing life with SJIA.

    Get resources

X